Burning Rock Biotech Limited

Ladies and gentlemen, thank you for standing by and welcome to the Building Rocks 2024 Quarter and Full Year Earnings Conference Call. Before we begin, I'd like to remind you that this conference call contains a forward-looking statement within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as real, expects, anticipates, future, intents, plans, beliefs, estimates, target, confident, and similar statements. Statements that are not historical facts, including statements about Burning Rock's beliefs and expectations, are forelooking statements. Such statements are based upon management's current expectations and current market and operating conditions, and relate to events that involve known or unknown risks, uncertainties, and other factors, all of which are difficult to predict and many of which are beyond Burning Rock's control. Fault looking statements involve risks, uncertainties, and other factors that could cause our results to differ materially from those contained in any such statements. Benning Rock does not undertake any obligation to update any fault looking statement as a result of new information, future events, or otherwise except as required under applicable law. Well, at this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question today, you need to press star 1 on your telephone. Please be advised that today's conference is being recorded. And I'd like to hand the conference over to the management team of Burning Rock. Thank you. Please go ahead.

Welcome to Burning Rock's earning conference call. This is Yusheng Han, the CEO and founder. Today you have our team consisting of CEO, Shannon Chai, CTO, Zhihong Zhang, and our CFO, Leo Li. Please turn to page three. Let's start. So Burning Rock is China's molecular diagnostic leader for persistent oncology. There are two main parts of our business. The first one is therapy selection and the second one is early detection. Let's turn to page four. So today we'll go through our 2020 recap and also we'll go through other issues such as 2021 priorities and financials. But what is more exciting is about our commercialization plan for our flood-based multi-cancer early detection.

Let's turn to page five.